Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Governement Health Belgium | Other Identifier | Stethoscoop federal governement heatlh Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this study, patients presenting with acute infections at risk of developing sepsis will be followed in their home setting using wearables that provide (semi-)continue monitoring of vital signs as well as through follow up using a designated smartphone application. This is an innovative pilot study that will examine the potential of transmural care through telemonitoring for the first time in patients at risk for developing sepsis. By allowing for active follow-up of vital parameters in a transmural setting, this project aims to reduce the number of hospitalizations as compared to current practice. Furthermore, we aim to the number of patients referred to the emergency department after a visit at their primary care physician. Thereby, we aim to reduce the healthcare burden, yet providing the ability for rapid intervention in case of detarioration of patients, thereby reducing morbidity and mortality as well as associated costs.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| (semi)continue monitoring of patients at risk for sepsis at home | Other | Patients with acute infections at risk of developing sespsis will be followed in their home setting using wearables that provide (semi-)continue monitoring of vital signs as well as through follow up using a desingated smarthphone application. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| (semi)continue monitoring of patients at risk for sepsis at home | Other | (semi)continue monitoring of patients at risk for sepsis at home |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of the development and roll out of a central medical center for monitoring at home | The total number of patients who use the home monitoring system for at least three days. This measure evaluates the adoption and feasibility of remote monitoring within a real-world setting. | From enrollment to the end of monitoring depending on the clinical evolution of the patient, with a minimum of one week and a maximum follow-up of three weeks. |
| Evaluation of the development and roll out of a central medical center for monitoring at home | The proportion of patients whose wearable devices and smartphone applications successfully capture at least 80% of the required physiological data over the home monitoring period. This assesses the reliability and consistency of the telemonitoring system. | From enrollment to the end of monitoring depending on the clinical evolution of the patient with a minimum follow-up of one week and up to a maximum of three weeks. |
| Evaluation of the development and roll out of a central medical center for monitoring at home | The effectiveness of telemonitoring wearables and smartphone applications in accurately measuring and tracking the National Early Warning Score (NEWS) in a home setting. This evaluates the clinical utility of remote patient monitoring for early detection of health deterioration. | From enrollment to the end of monitoring depending on the clinical evolution of the patient with a minimum follow-up of one week and up to a maximum of three weeks of follow-up. |
| Evaluation of the development and roll out of a central medical center for monitoring at home | The number of emergency departments and primary care physicians actively using the telemonitoring platform to access and review patient data. This assesses the level of integration of home monitoring into routine clinical workflows. | From enrollment to the end of monitoring depending on the clinical evolution of the patient with a minimum follow-up of one week and up to a maximum of three weeks of follow-up. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patients that are severely ill and require immediate hospitalization Qucik Sepsis Related Organ Failure score (QSOFA) ≥ 1 National Early Warning Score (NEWS) ≥ 5
Patients that demonstrate confusion, changes in mental state and/or an Mini-Mental State Examination (MMSE) below 26
Presence of neuropenic fever
Patients currently undergoing immunosuppressive therapy or chemotherapy
Patients with human immunodeficiency virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS)
Suspicion of appendicitis, suspicion of meningitis or meningeal irritation, suspicion of or high risk of developing endocarditis
Complicated operation wounds at the time of screening
Proven pneumonia (CURB 65 score ≥ 1)
Emphysema, Chronic Obstructive Pulmonary Disease (COPD) GOLD >1 or interstitial lung disease
Patients with oxygen at home > 2 l/min on a chronic basis (severe underlying lung disease?)
Severe cardiovascular disease including:
Acute chest pain (suspicion of acute coronary pathology)
Suspicion of/chance of septic arthritis
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Celine Maes, PHD | Contact | +32 3 436 81 65 | thuisopvolging@uza.be |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Antwerp University Hospital (UZA) | Recruiting | Edegem | Antwerpen | 2650 | Belgium |
The results will be published in a research paper in a scientific journal.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018805 | Sepsis |
| D007239 | Infections |
| ID | Term |
|---|---|
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided